Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.07.03.663001

Direct Visualization of Anesthesia-induced Subcellular Dysfunction in Non-Neuronal Tissues of C. elegans

Abstract

Volatile anaesthetics such as isoflurane, halothane, and sevoflurane are extensively utilized for their reversible induction of unconsciousness, exhibiting well-defined impacts on neural networks. However, their influence on non-neuronal and developing tissues is inadequately comprehended, generating concerns for vulnerable categories, including children and individuals receiving extended anesthesia. To rectify this deficiency, we examined the subcellular impacts of anaesthetics utilizing HEK 293T and HepG2 cell lines, alongside with Caenorhabditis elegans as a comprehensive organismal model. In vitro treatment to lidocaine and isoflurane resulted in mitochondrial depolarization, lysosomal aggregation, and buildup of reactive oxygen species (ROS). In vivo, 8% isoflurane induced mitochondrial fragmentation, loss of branching, and disruption of tubular lysosomes, indicating compromised energy metabolism and autophagic stress. We detected selective transcriptional inhibition of neuron- and immune-related promoters, although RNA Pol I remained active, indicating energy-conservation strategies. Systemic oxidative stress was validated by TIR-1::GFP aggregation and lipofuscin accumulation. Our research is one of the initial investigations that defines anaesthesia-induced subcellular dysfunction beyond the nervous system, providing novel insights for safer anaesthetic protocols and informing long-term health evaluations, especially in individuals who are developing or chronically exposed. Significance statementWhile volatile anaesthetics are widely used for inducing unconsciousness, their effects beyond neurons remain poorly understood. This study reveals that clinically used anaesthetics such as isoflurane and lidocaine cause profound subcellular dysfunction in non-neuronal systems, including mitochondrial depolarization, lysosomal disruption, transcriptional repression, and systemic oxidative stress. Using both human cell lines and Caenorhabditis elegans, we uncover conserved patterns of organellar damage and stress responses. These findings have critical implications for pediatric, intensive care, and long-term anaesthesia cases, urging the need to reassess anaesthetic safety profiles and develop biomarkers for systemic toxicity. Our work opens new avenues for designing cell-type-specific protective strategies under anaesthetic exposure.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mukherjee, B., Chandra, S., Salam, A., Behera, L., Nandi, C. K.. 2025-07-06. Direct Visualization of Anesthesia-induced Subcellular Dysfunction in Non-Neuronal Tissues of C. elegans. https://doi.org/10.1101/2025.07.03.663001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Molecular Dosimetry of DNA Adducts in Mice Exposed to Ethylene Oxide

Ethylene oxide (EtO) is a highly reactive industrial chemical and classified as a known human carcinogen with a putative mutagenic mode of action (MOA). Its genotoxic potential is primarily mediated through alkylation of DNA, resulting in the formation of the mutagenic adduct O6-(2-hydroxyethyl)-2-deoxyguanosine (O6-HE-dG). The N7-(2-hydroxyethyl)guanine (N7-HE-G) adduct is formed in greater abundance and is generally considered to be non-mutagenic. However, dose-response relationships of these DNA adducts, particularly at low inhalation exposure levels (i. e., below 3 ppm), remain unknown. These data are necessary to inform the biological plausibility of different statistical dose-response models that have been applied to human or animal data used for cancer risk assessment. In the present study, male and female B6C3F1 mice were exposed to EtO (0, 0.05, 0.1, 0.5, 1, 50, 100, and 200 ppm) 6 hours/day for 28 consecutive days. Immediately following the last exposure, DNA was extracted from lung, liver, bone marrow, and mammary gland, and further utilized to measure DNA adduct levels using highly sensitive mass spectrometry platforms. N7-HE-G was detected in all tissues and exposure groups, showing linear dose-response relationships in the low-dose range ([&le;]1 ppm) and increased sharply and exposure-disproportionately in the high-dose range ([&ge;]50 ppm). Despite a very low limit of detection, O6-HE-dG, in contrast, was not detected at exposures <50 ppm in any tissue consistent with at most a shallow linear exposure response. At higher exposures ([&ge;]50 ppm), O6-HE-dG exhibited a dose-response pattern of N7-HE-G. Notably the mammary gland, despite being anatomically distant from the site of inhalation, exhibited the second-highest levels of both adducts at higher doses. This study provides the first reliable quantitative dose-response evidence of DNA adducts in tumor target and non-target (liver) tissues across a wide range of EtO exposures. The two DNA adducts differ markedly in their abundance, repairability and mutagenic potential and together provide a molecular MOA dose-response framework to inform both quantitative cancer risk assessment and genotoxic hazard characterization.

pharmacology and toxicology↗